

Provided by:



## Endocrine Cancer Tumor Board 2023-2024

**Endocrine Cancer Tumor Board 2023-2024 - 6/13/2023**

**June 13, 2023**

**7:00 AM - 8:00 AM**

**Virtual Tumor Board**

### **Target Audience**

This program has been designed for Anesthesiology, Diagnostic Radiology, Emergency Medicine, Family Medicine, Pediatrics, Clinical Genetics And Genomics (Md), Interventional Radiology And Diagnostic Radiology, Nuclear Medicine, Internal Medicine - Medical Oncology, Pathology - Clinical, Radiation Oncology, Surgery, Vascular Surgery, Internal Medicine - Endocrinology, Diabetes And Metabolism, Internal Medicine, Otolaryngology, Pathology - Anatomic, Medical Genetics And Genomics - Medical Biochemical Genetics, Clinical Cytogenetics And Genomics, Clinical Molecular Genetics And Genomics, Laboratory Genetics And Genomics, Medical Genetics And Genomics - Molecular Genetic Pathology, Otolaryngology - Plastic Surgery Within The Head And Neck, Pathology - Cytopathology, Pathology - Hematopathology, Pathology - Pathology-Chemical, Pathology - Pathology-Molecular Genetic, Pediatrics - Pediatric Endocrinology, Pediatrics - Pediatric Hematology-Oncology, Pediatrics - Pediatric Infectious Diseases, Radiology , Radiology - Neuroradiology, Radiology - Nuclear Radiology, Surgery - Complex General Surgical Oncology, Pathology-Anatomic/Pathology-Clinical, All Specialties

### **Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Review the care of complex patients with thyroid cancers and neoplasms.
- 2 Discuss the evidence-based guidelines for thyroid tumors.
- 3 Discuss multi-disciplinary management strategies for patients with thyroid cancers and neoplasms.

### **Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Designation of Credit**

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is for **1.00** contact hours.

**Pharmacists:** This activity is not approved for pharmacy contact hours

For more information, please contact

**Pamela Sellers**

**(215) 349-8109**

**[pamela.sellers@penntmedicine.upenn.edu](mailto:pamela.sellers@penntmedicine.upenn.edu)**

**Check your transcript online at <https://upenn.cloud-cme.com>**

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

**Approved for (PSRM) patient safety/risk management designation**

**Acknowledgement of Commercial Support\***

None

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant and, applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

<b>Name of individual</b>	<b>Individual's role in activity</b>	<b>Name of Ineligible Company(s) / Nature of Relationship(s)</b>
Rachel Kelz, MD	Co-Director	Nothing to disclose - 09/27/2022
Heather Wachtel, MD	Course Director, Faculty	Nothing to disclose - 07/11/2022
Pamela Sellers, BSN	Nurse Planner	Nothing to disclose - 05/09/2023
Zubair Baloch, MD, PH	Other Planning Committee Member	Nothing to disclose - 09/02/2022
Jessica S Berman, MD	Other Planning Committee Member	Nothing to disclose - 10/11/2022
Robert Brody, MD	Other Planning Committee Member	Nothing to disclose - 07/19/2022
Ara Chalian, MD	Other Planning Committee Member	Nothing to disclose - 11/16/2022
Michelle S Gentile, MD, PhD	Other Planning Committee Member	Nothing to disclose - 05/12/2023
Jalal Jalaly, MD	Other Planning Committee Member	Nothing to disclose - 03/16/2023
Kristen Noelle Kobaly, MD	Other Planning Committee Member	Nothing to disclose - 05/03/2023
Virginia A LiVolsi, MD	Other Planning Committee Member	Nothing to disclose - 09/07/2022
Susan J Mandel, MD	Other Planning Committee Member	Nothing to disclose - 03/13/2023

Kathleen Montone, MD-FCBC	Other Planning Committee Member	Nothing to disclose - 12/08/2022
Daniel Pryma, MD	Other Planning Committee Member	Consulting Fee-Progenics (Relationship has ended)  Membership on Advisory Committees or Review Panels, Board Membership, etc.-MTTI  Stocks or stock options, excluding diversified mutual funds-MTTI  Membership on Advisory Committees or Review Panels, Board Membership, etc.-Trevarx  Stocks or stock options, excluding diversified mutual funds-Trevarx  Consulting Fee-Curium (Relationship has ended)  Consulting Fee-Siemens Medical Solutions, Inc. (Relationship has ended)  Consulting Fee-Bayer (Relationship has ended) - 12/01/2022
Lova Sun, MD	Other Planning Committee Member	Honoraria-Regeneron Pharmaceuticals, Inc. (Relationship has ended) - 11/04/2022

All relevant financial relationships have been mitigated.

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit where the business lines of the ineligible company relate to the content of the activity. Financial interests are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.